Literature DB >> 8250990

Generalized osteoarthritis associated with increased insulin-like growth factor types I and II and transforming growth factor beta in cortical bone from the iliac crest. Possible mechanism of increased bone density and protection against osteoporosis.

J Dequeker1, S Mohan, R D Finkelman, J Aerssens, D J Baylink.   

Abstract

OBJECTIVE: To investigate whether growth factors stored in bone might explain the increased bone density and resistance to osteoporosis in generalized osteoarthritis.
METHODS: Levels of insulin-like growth factor (IGF) types I and II and transforming growth factor beta (TGF beta) were measured in extracts of cortical bone from the iliac crest obtained at necropsy from subjects with or without osteoarthritis of the hands.
RESULTS: Concentrations of IGF-I, IGF-II, and TGF beta were significantly higher in extracts of bone powder from subjects in the osteoarthritis group than in extracts from subjects in the control group.
CONCLUSION: The results suggest that the increased bone density and resistance to osteoporosis in patients with osteoarthritis may be associated with increased skeletal concentrations of IGF-I, IGF-II, and TGF beta and may reflect a generally increased biosynthetic activity of osteoblasts in these patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250990     DOI: 10.1002/art.1780361209

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

1.  Lack of in vitro evidence for storage of 1,25-dihydroxycholecalciferol (1,25(OH)2D3) and 1,25(OH)2D3 binding protein in skeletal matrix.

Authors:  S Boonen; J Aerssens; I Jans; E Van Herck; I Vandewal; J Peeters; R Van den Eynde; J Dequeker; R Bouillon
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

2.  The relationship between osteoarthritis and osteoporosis in the spine.

Authors:  L Y Dai
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 3.  Targeting subchondral bone for treating osteoarthritis: what is the evidence?

Authors:  Steeve Kwan Tat; Daniel Lajeunesse; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-02       Impact factor: 4.098

4.  Bone mineral density and bone turnover in spinal osteoarthritis.

Authors:  J Dequeker; J M Mbuyi-Muamba
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

Review 5.  Sex hormones and the risk of osteoarthritis in women: epidemiological evidence.

Authors:  M C Nevitt; D T Felson
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

6.  The relationship between knee osteoarthritis and osteoporosis.

Authors:  Ilhan Sezer; Ozge G Illeez; Serpil D Tuna; Nilufer Balci
Journal:  Eurasian J Med       Date:  2010-12

7.  Effects of alfacalcidol alone or in combination with elcatonin on incidence of osteoporotic vertebral fractures in postmenopausal women with spondylosis.

Authors:  Naohisa Miyakoshi; Yoichi Shimada; Shigeru Ando; Takashi Minato; Eiji Itoi
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: the MOST study.

Authors:  M C Nevitt; Y Zhang; M K Javaid; T Neogi; J R Curtis; J Niu; C E McCulloch; N A Segal; D T Felson
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

9.  Local leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression.

Authors:  Marie-Solange Mutabaruka; Mohamed Aoulad Aissa; Aline Delalandre; Martin Lavigne; Daniel Lajeunesse
Journal:  Arthritis Res Ther       Date:  2010-02-08       Impact factor: 5.156

10.  Effect of local TGF-beta1 and IGF-1 release on implant fixation: comparison with hydroxyapatite coating: a paired study in dogs.

Authors:  Anders Lamberg; Joan E Bechtold; Jørgen Baas; Kjeld Søballe; Brian Elmengaard
Journal:  Acta Orthop       Date:  2009-08       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.